Zhou Xiaozhou, Tian Zijian, Li Shaoyun, Jing Ruifeng, Liu Ziqing, Wu Peng, Shao Jian, Bai Jie, Huang Rong, Pan Ying, Zhou Kaixin
College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China.
Guangzhou National Laboratory, Guangzhou, Guangdong, China.
Front Med (Lausanne). 2025 May 14;12:1576029. doi: 10.3389/fmed.2025.1576029. eCollection 2025.
Metabolic-associated fatty liver disease (MAFLD) is a prevalent chronic liver condition with significant health implications. Fermented Cordyceps Preparation (FCP) has shown promise in managing metabolic disorders, prompting interest in its potential for MAFLD prevention. There is, however, a lack of large-scale clinical evidence regarding its preventive efficacy and long-term safety.
We aimed to assess the preventive efficacy and safety of FCP, as regards combatting MAFLD.
Propensity score matching was used to select 343 FCP users and 1372 non-users with metabolic syndrome, (MS) as recorded in EMR. These two groups were followed for 750 days, to track the incidence of MAFLD. The Kaplan Meier method was used to calculate the cumulative risk of MAFLD events in each subgroup. A Multiple linear regression model was used to compare the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as between the two groups.
Compared with non-users, FCP users were associated with a 26% decreased risk of MAFLD (hazard ratio 0.74, 95% confidence interval 0.56-0.97). During the follow-up, the changes in both ALT and AST, were insignificantly different between the two groups.
These findings highlight the potential of FCP in MAFLD prevention and offer insight into its safety profile, suggesting avenues for further clinical validation and drug repurposing efforts.
代谢相关脂肪性肝病（MAFLD）是一种常见的慢性肝脏疾病，对健康有重大影响。发酵虫草制剂（FCP）在管理代谢紊乱方面已显示出前景，这引发了人们对其预防MAFLD潜力的兴趣。然而，关于其预防效果和长期安全性缺乏大规模临床证据。
我们旨在评估FCP在对抗MAFLD方面的预防效果和安全性。
采用倾向得分匹配法，从电子病历记录的代谢综合征（MS）患者中选取343名FCP使用者和1372名非使用者。对这两组进行750天的随访，以追踪MAFLD的发病率。采用Kaplan Meier方法计算每个亚组中MAFLD事件的累积风险。使用多元线性回归模型比较两组之间丙氨酸氨基转移酶（ALT）和天冬氨酸氨基转移酶（AST）的水平。
与非使用者相比，FCP使用者患MAFLD的风险降低了26%（风险比0.74，95%置信区间0.56-0.97）。在随访期间，两组之间ALT和AST的变化无显著差异。
这些发现突出了FCP在预防MAFLD方面的潜力，并提供了对其安全性概况的见解，为进一步的临床验证和药物重新利用工作指明了方向。
